Essen Biotech
Clinical trials sponsored by Essen Biotech, explained in plain language.
-
Immune cell therapy takes on Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new treatment called EBNK-001, which uses donor natural killer (NK) cells to fight advanced solid tumors. About 83 adults with cancers like lung, breast, or colorectal cancer that have not responded to standard treatments will receive the NK cells along with ch…
Phase: PHASE1, PHASE2 • Sponsor: Essen Biotech • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New cell therapy targets Hard-to-Treat cancers using Biopsy-Guided strategy
Disease control Recruiting nowThis study tests a treatment using donor immune cells (CAR-NK cells) designed to attack cancer. The specific target on the cancer cells is chosen based on a biopsy of the tumor or a blood test. The goal is to see if this approach is safe and can shrink or control advanced solid t…
Phase: PHASE1, PHASE2 • Sponsor: Essen Biotech • Aim: Disease control
Last updated May 13, 2026 15:59 UTC